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The instant blood-mediated inﬂammatory reaction
(IBMIR) is a major obstacle to the engraftment of
intraportal pig islet xenografts in primates. Higher
expression of the galactose-a1,3-galactose (aGal)
xenoantigen on neonatal islet cell clusters (NICC)
than on adult pig islets may provoke a stronger
reaction, but this has not been tested in the baboon
model. Here, we report that WT pig NICC xenografts
triggered profound IBMIR in baboons, with intravascu-
lar clotting and graft destruction occurring within
hours, which was not prevented by anti-thrombin
treatment. In contrast, IBMIR was minimal when
recipients were immunosuppressed with a clinically
relevant protocol and transplanted with NICC from
aGal-deﬁcient pigs transgenic for the human comple-
ment regulators CD55 and CD59. These genetically
modiﬁed (GM) NICC were less susceptible to humoral
injury in vitro than WT NICC, inducing signiﬁcantly less
complementactivationandthrombingenerationwhen
incubated with baboon platelet-poor plasma. Recipi-
entsofGMNICCdevelopedavariableanti-pigantibody
response, and examination of the grafts 1 month after
transplant revealed signiﬁcant cell-mediated rejection,
although scattered insulin-positive cells were still
present. Our results indicate that IBMIR can be
attenuated in this model, but long-term graft survival
may require more effective immunosuppression or
further donor genetic modiﬁcation.
Keywords: Hyperacute rejection, instant blood-medi-
atedinﬂammatoryreaction, neonatalisletcellclusters,
thrombosis, type 1 diabetes, xenotransplantation
Abbreviations: aGal, galactose-a1,3-galactose; GM,
genetically modiﬁed; GTKO, GGTA1 gene knockout;
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CD55, CD59 and a1,2-fucosyltransferase (H-transfer-
ase, HT); HBBS, Hanks Buffer Salt Solution; HSA,
human serum albumin; IBMIR, instant blood-mediated
inﬂammatory reaction; IEQ, islet equivalent; MMF,
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anti-thrombin; TGA, thrombin generation assay
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Introduction
Isletallotransplantationhasbecomeanacceptedtreatment
for a subset of patients with type 1 diabetes, but limited
organ donor numbers prevent its more universal applica-
tion. To overcome this shortage, xenotransplantation using
pig islets has been proposed as a potential alternative. Both
adult pig islets and neonatal islet cell clusters (NICC), which
are easier to isolate (1), have been considered. While NICC
have survived and functioned in the short to medium term
in cynomolgus monkeys (2), rejection remains a major
barrier to clinical application. Most studies have focused on
preventing the T cell–mediated cellular immune response,
using immunosuppressive protocols that are not clinically
applicable (3). A more immediate problem is early islet loss
due to inﬂammatory and thrombotic mechanisms. The
preferred site for human islet allotransplantation is the liver
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1300via the portal circulation, where islets directly contact the
blood (4). Bennet et al (5) demonstrated that contact of
adult pig islets with human blood in vitro or cynomolgus
monkey blood in vivo triggered an immediate inﬂammatory
response that included activation of the complement and
coagulation cascades and rapid clot formation with islet
destruction. A similar reaction occurs when human islets
weremixed withhumanblood, suggestingthat nonspeciﬁc
factors such as exposure of pro-coagulants contribute
to this instant blood-mediated inﬂammatory reaction
(IBMIR) (6,7). Complement activation is an initiating factor
in IBMIR, and complement inhibitors are being trialed in
islet allotransplantation (8). The potential for complement
activation via the alternative pathway is probably greater in
xenotransplantation (9).
If pig NICC are to become a viable alternative therapy for
clinical islet replacement, they must survive IBMIR and
providelong-termfunction.PreviousobservationsofIBMIR
in primates are limited to studies of adult pig islets
transplanted into monkeys (5,10). Unlike adult islets,
NICC strongly express the xenoantigen galactose-a1,3-
galactose (aGal), making themsusceptibleto the bindingof
preformed anti-aGal antibodies. This is likely to amplify
complement activation, promoting IBMIR and thrombo-
sis(11–13).BalancingthisisthefactthatNICCpreparations
contain less contaminating prothrombotic material (13).
The use of donor pigs lacking aGal (GTKO) has been shown
to improve engraftment of NICC in macaques (14). Another
group reported long-term function of transgenic adult pig
isletsexpressingthehumancomplementregulatorCD46in
cynomolgus monkeys (15). However, the combination of
GTKO and transgenic complement regulation has not been
examined. The initial aim of this study was to characterize
IBMIR in baboons transplanted intraportally with WT pig
NICC. We then examined whether NICC from GTKO pigs
expressing human CD55 and CD59 were protected from
IBMIR in recipient’s immunosuppressed with a clinically
relevant protocol. Finally, we monitored the survival of
these genetically modiﬁed (GM) NICC xenografts up to
1 month after transplant, by histological analysis.
Materials and Methods
Recipient animals and ethics clearances
Baboons (Papio hamadryas) were supplied by the NH&MRC Australian
National Baboon Colony, Sydney, Australia. All procedures were approved
by Local Area Health Service Animal Ethics Committees and conducted in
compliance with State Government legislation and NH&MRC Animal
Research Guidelines.
Donor pigs
WT piglets were Large White/Landrace cross. GTKO piglets that co-
expressed human CD55, CD59 and a1,2-fucosyltransferase (H-transferase,
HT) (GTKO/CD55-CD59-HT) were generated by mating GTKO/CD55-CD59-
HT pigs with GTKO pigs. Piglets were screened by ﬂow cytometry of
peripheral blood mononuclear cells(16) foraGal and CD55 (data notshown);
the level of expression in the transgenic line has been previously reported
(17). Parental GTKO/CD55-CD59-HT pigs were generated by breeding
heterozygous CD55-CD59-HT (17) onto the GTKO (18) background.
Preparation of NICC
Pancreata were obtained from 1- to 5-day-old piglets. NICC were produced
using a modiﬁcation of a previously described technique (1). Brieﬂy,
pancreata were ﬁnely chopped and digested with 2.5mg/mL Collagenase
Type V (Sigma–Aldrich, St. Louis, MO) at 378C. Washed tissue was plated
into Petri dishes containing Hams F-10 medium (Thermo Trace, Melbourne,
Australia) and 1% pooled autologous pig sera. The cells were cultured for
6 days at 378C and 5% CO2. Prior to transplantation, NICC purity was
determined by quantitative image analysis.
NICC transplantation into baboons
All surgical procedures were carried out under general anesthesia with 1–
2% isoﬂurane in oxygen. Following midline incision, the portal and hepatic
veins were identiﬁed. An arrow double-lumen venous cannula was inserted
in the portal vein for NICC infusion under gravity.
Of four baboons receiving WT NICC, two were given 500U/kg body weight
recombinant human anti-thrombin (rhAT; GTC Biotherapeutics, Framing-
ham, MA) infused over 20–25min; 10–15min prior to NICC infusion. This
was expected to increase circulating AT activity to 15–20U/mL (16). No
immunosuppression was given to WT NICC recipients, but all received
intravenous (IV) heparin (100IU/kg recipient weight) prior to NICC infusion.
Five baboons transplanted with GTKO/CD55-CD59-HT NICC received
heparin plus an immunosuppressive regimen based on our clinical islet
transplant protocol (19). For the ﬁrst 3 days, the animals were given 33mg
ATG (Fresenius Biotech GmbH, Bad Homburg, Germany) IV and twice daily
500mg IV mycophenolate mofetil (MMF; CellCept
1, Roche, Sydney,
Australia). Thereafter, they received twice-daily oral doses of 500mg
MMF and 4.0mg/kg Tacrolimus (Prograf, Janssen-Cilag Pty Limited,
Sydney, Australia) with the dose adjusted to achieve a target trough
concentration of 10–15ng/mL.
Blood and plasma analysis
Total white and red cell counts and platelet and differential leukocyte counts
of EDTA-treated blood were obtained using a cell counter (Advia 120
Hematology System; Siemens Healthcare, Erlangen, Germany). Comple-
mentactivationproductC3ainplasmawasmeasuredusingsandwichELISA
kits (Quidel, San Diego, CA).
Measurement of non-Gal antibodies
Heat-inactivated serum samples were diluted 1/10 and incubated at room
temperature with endothelial cells from GTKO and WT pigs. Cells were
washed and incubated with either FITC conjugated goat (Fab’) anti-human
IgM(SouthernBiotech,Birmingham, AL)or IgG(g-chainspeciﬁc)(Sigma,St.
Louis, MO). Cells were then washed, resuspended in FACS buffer and
analyzed on a FACSCalibur Flow Cytometer (Becton Dickinson, San Diego,
CA) using FlowJo software (Tree Star, Ashland, OR).
Complement activation
The 1000 islet equivalent (IEQ) NICC in 500mL Hanks Buffer Salt Solution
without CaCl2 (HBSS) with 1% human serum albumin (HSA) (Albumex
120,
CSL,Victoria,Australia)wasaddedto500mLofplatelet-poorplasma(PPP)in
a nontissue culture-treated plate (BD Biosciences, San Jose, CA) agitated at
120 rpm at 378C. A cytometric bead array kit for human anaphylatoxin was
used (BD Biosciences) to analyze the supernatant.
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Thrombin generation assay (TGA) was performed using a Calibrated
Automated Thrombogram and ﬂuorometer FLx800 with BIOTEK—Gen 5
software(BioTekInstruments,Winooski,VT).PPPwasaddedtoamicrotiter
plate with 250 IEQ NICC in 40mL of HBSS/1% HSA or 40mL of HBSS/1%
HSA control. The reaction was started with 50mL of 1mM ﬂuorogenic
substrate (Z-GGR-AMC) and 15mM CaCl2 (Technothrombin
1 TGA;
Technoclone GmbH, Vienna, Austria). Fluorescence was measured for
120min at 378C (excitation 390nm, emission 460nm).
Liver biopsy for histology
In WT NICC transplanted baboons, slice biopsies were taken from different
areas of the liver at 0, 10, 20 and 30min and then at 30-min intervals until
300min. Thereafter,wedgeexcisionbiopsies were takenat60-minintervals
until the liver had infarcted. Care was taken to ensure that traumatic artifact
of the liver was avoided. Liver biopsies were taken from recipients of GM
NICC at 60min and 14, 21 and 30 days posttransplant, using a previously
described method (20). At the end of the study period, baboons were
re-anesthetized and the liver was removed for histology prior to euthanasia.
Histology and immunohistochemical staining
Baboon liver biopsy samples were divided and either mounted in OCT
embedding medium (Tissue-Tek; Miles, Naperville, IL) and snap-frozen in
liquid nitrogen, or placed in formalin ﬁxative and parafﬁn-embedded.
Sections were stained for platelet deposition using an anti-human platelet
glycoprotein GPIIb/IIIa mAb (R&D Systems, Minneapolis, MN). For
detection of inﬁltrating T and B cells, sections were stained using anti-
human CD3 and CD20cy antibodies (Dako Australia, Botany, Australia),
respectively. Staining for aGal was performed with an anti-aGal mAb (21).
Image analysis of liver biopsies
Stained liver biopsy sections were scanned with an Aperio Image-Scope
Scanner (Leica Microsystems, Wetzlar, Germany). Sections were stained
with Martius Scarlet Blue (MSB) trichrome, for clot analysis, with
chromogranin A and hematoxylin for analysis of percent NICC present,
and with anti-human CD3 and CD20cy and hematoxylin for analysis of
percent T and B lymphocytes present. Eight 1mm
2 sections were randomly
selected from each image and the automated image analysis algorithm
Aperio Positive Pixel Count v9 was used to quantify the amount of clot (red
blood cells [RBCs]þﬁbrin) and RBCs alone. This utilized inclusion exclusion
analysis rather than gating of speciﬁc areas. Two annotations were
performed on each square; the ﬁrst with a hue value of 1.0 to quantify
thetotalclot(redandyellowstaining)andthesecondwithahuevalueof0.25
to quantify the RBCs only (yellow staining). The annotations were used to
determine the hue value between the positively stained areas (brown) and
thehematoxylin-stainedbackground.Thealgorithmcountedthenumberand
intensity sum in each intensity range and from this generated a positivity
value (the total number of positive pixels divided by the total number of
positive and negative pixels), which was used to determine the percentage
of the 1mm
2 liver section detected as positive for either total clot or RBCs
only staining. The percentage of ﬁbrin was determined by subtracting the
percentage RBC from the percentage total clot. NICC were calculated as
number present per section analyzed; for T and B cells, the percentage of
islet area staining positive was calculated.
Statistical analysis
TheLinearMixedEffectsModel(22)wasusedtoevaluatethehematological
parameters, taking into account the variance of readings taken on the same
blood donor for each variable. Generalized estimating equations were used
to test for changes in hematological parameters over time, taking into
account the dependence of readings taken on the same baboon. Mean
values with standard deviation are shown unless otherwise indicated.
Statistical software used for data analysis was S-Plus 6 for Windows
(Insightful Corporation, Seattle, WA). p<0.05 was considered signiﬁcant.
Results
Production of porcine NICC
NICC were isolated from either WT piglets (n¼30) or from
GTKO piglets co-expressing human CD55, CD59 and
a1,2-fucosyltransferase (HT) (n¼53). There was no signiﬁ-
cant difference in the yield of NICC between WT and
GTKO/CD55-CD59-HT piglets (Table 1). Purity was not
Table 1: Summary data for baboontransplants performedincludingthe NICC yields from WT and GTKO/CD55-CD59-HT piglet pancreases
used for transplantation
Baboon
Weight
(kg) Donors
Total no.
of NICC
NICC/g
pancreas
Total no.
of IEQ
IEQ/g
pancreas NICC/kg IEQ/kg
Total no. of
NICC/mm
3
liver
rhAT (U)
total dose
WT1 21 WT 547500 39360 185432 13330 26071 8830 0.0276 10500
WT2 22 WT 547500 39360 185432 13330 24886 8429 0.0260 None
WT3 24 WT 508750 24261 156396 7461 21198 6517 0.0231 12000
WT4 23 WT 508750 24261 156396 7461 22120 6800 0.0241 None
Mean 528125 31811 170914 10396 23569 7644 0.0252
SD 22372 8717 16764 3388 2289 1156 0.0020
GM1 12 GTKO/CD55-CD59-HT 491505 22525 135654 6217 40959 11305 0.0223 None
GM2 12 GTKO/CD55-CD59-HT 445500 25766 111927 6474 37125 9327 0.0222 None
GM3 10 GTKO/CD55-CD59-HT 318750 12340 53875 2086 31875 5388 0.0177 None
GM4 10 GTKO/CD55-CD59-HT 805000 23802 224124 6627 80500 22412 0.0447 None
GM5 8 GTKO/CD55-CD59-HT 783133 27459 328103 11504 97892 41013 0.0502 None
Mean 568778 22378 170737 6582 57670 17889 0.0314
SD 215309 5918 107192 3339 29605 14389 0.0148
GM, genetically modiﬁed; IEQ, islet equivalent; NICC, neonatal islet cell clusters; rhAT, recombinant human anti-thrombin; SD, standard
deviation.
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GTKO/CD55-CD59-HT NICC (91 2.8%).
WT porcine NICC cause rapid thrombosis when
transplanted intraportally in baboons
The 7644 1156 IEQ WT pig NICC/kg of body weight were
transplanted intraportally into four healthy nondiabetic
baboons without (n¼2) or with (n¼2) treatment with
500U rhAT/kg of body weight. Large baboons (21–24kg)
were used to enable multiple biopsies with minimal
trauma to the liver. The dose of rhAT was based on our
previous CD55-CD59-HT transgenic pig renal xenograft
studies (16,17), and resulted in peak AT levels of 10–
15U/mL (17). There was substantial intraportal clot
formation regardless of rhAT therapy, with biopsies
showing NICC surrounded by clot containing ﬁbrin, RBC
and leukocytic inﬁltrate from as early as 1h posttransplant
(Figure 1). One of the rhAT-treated recipients developed
a complete left portal vein thrombosis when the NICC
were infused selectively toward the left lobe of the liver. A
mechanical component cannot be excluded as being
partially responsible for this. However, NICC were identi-
ﬁed in the right liver lobe and hepatic vein in this recipient
(Figure 1B), surrounded by intraportal clot (Figure 1C)
despite the main portal vein to these liver segments
remaining patent. Most NICC were surrounded by mono-
cytes and neutrophils with areas staining for C3c
(Figure 1D) in surrounding clot. Neutrophils were seen
inﬁltrating NICC that stained positive for IgG deposition,
leading to early destruction (Figure 1E–F). Quantiﬁcation of
NICC in end point biopsies demonstrated similar numbers
in all recipients (Table 1).
Intraportal GTKO/CD55-CD59-HT NICC xenografts do
not cause thrombosis in immunosuppressed
recipients
GTKO/CD55-CD59-HTNICCweretransplantedintraportally
into ﬁve nondiabetic baboons. Expression of human CD55
and CD59 on the NICC prior to transplantation was
conﬁrmed by immunohistochemistry (Figure S1). Two
modiﬁcations were made to the protocol to allow for the
possibility that these NICC would survive beyond IBMIR
and could be monitored by histological analysis. First, the
number of early biopsies was reduced to one (at 1h),
permitting the use of smaller recipients (8–12kg) and as a
consequence approximately doubling the relative number
ofNICCtransplanted(17889 14389IEQ/kg).Second,the
recipients were treated with a clinically relevant immuno-
suppressive protocol.
None of the recipients showed evidence of thrombosis.
Analysis of 1-h biopsies showed intact NICC surrounded by
normal vasculature, with some erythrocytes but no
platelets, ﬁbrin or clot. A representative example is shown
in Figure 2. Although most of the NICC observed appeared
tobefreeﬂoating,itismorelikelythattheimagesrepresent
tangential sections of NICC in contact with the vessel wall.
AnexampleofthelessfrequentlyobservedcaseofanNICC
Figure 1: Evidence of instant blood-mediated inﬂammatory reaction in baboons transplanted intraportally with WT pig NICC.
One-hourposttransplantbaboonliverbiopsieswerestainedwithMartiusScarletBlue(A,C)orH&E(E),orforaGal(B),complementC3c(D)
orIgG(F).Massiveclottingcanbe seenaroundtheaGal-positive (B)NICC, alongwithleukocyteinﬁltration (E)anddepositionofC3c(D) and
IgG (F). All images  20 magniﬁcation except C ( 10). NICC, neonatal islet cell clusters.
Genetically Manipulated NICC Stop Thrombosis
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evidence of thrombus, is shown in Figure S2. No
lymphocytic inﬁltrate was seen. The xenografts showed
strong expression of CD55 and CD59 (Figure 2C and D) and
absence of aGal (Figure 2E).
Analysis of end point (1 month) biopsies demonstrated
NICC in similar numbers (Table 1) in all lobes. There was no
evidence of thrombosis (Figure 3A and B), and scattered
cells staining for chromogranin A, insulin, glucagon or
somatostatinwereobserved(Figure3C–F).However,most
Figure 2: Absence of early thrombosis in immunosuppressed baboons transplanted intraportally with GTKO/CD55-CD59-HT
NICC. One-hour posttransplant liver biopsies stained with hematoxylin and eosin (A) or Martius Scarlet Blue (B) showed intact NICC
surrounded by normal vasculature, with some erythrocytes but no platelets, ﬁbrin or clot present in either the micro- or macro-vasculature.
Staining conﬁrmed that the NICC expressed human CD55 (C) and CD59 (D) but not aGal (E). All images  20 magniﬁcation. GTKO/CD55-
CD59-HT, GTKO pigs expressing human CD55, CD59 and a1,2-fucosyltransferase (H-transferase, HT); NICC, neonatal islet cell clusters.
Figure3: LackofthrombosisandevidenceofcellularrejectionofGTKO/CD55-CD59-HTNICCxenografts1monthaftertransplant.
Baboonliversectionswerestainedwithhematoxylinandeosin(A),MartiusScarletBlue(B),orantibodiesforchromograninA(C),insulin(D),
glucagon (E), somatostatin (F), CD3 (G) or CD20 (H). All images  20 magniﬁcation. GTKO/CD55-CD59-HT, GTKO pigs expressing human
CD55, CD59 and a1,2-fucosyltransferase (H-transferase, HT); NICC, neonatal islet cell clusters.
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(Figure 3G and H). Image analysis (percent of NICC area
staining for CD3 or CD20) revealed a signiﬁcant increase in
T and B cells inﬁltrating the grafts over time, with more
T cells at 2 weeks and similar numbers of T and B cells at
1 month (Figure 4). Two-week biopsies conﬁrmed the
absence of thrombosis and the early signs of cellular
rejection at this time (FigureS3). Porcine C-peptide was not
detected at either 2 weeks or 1 month, presumably due to
the immaturity of the NICC, ongoing cellular rejection and
the use of nondiabetic recipients.
Quantitative analysis demonstrated heavy red cell seques-
tration and ﬁbrin deposition in clots in the liver of baboons
transplanted with WT NICC within hours of transplant. The
mean percentage of clot was 2.5 0.36% of the total
biopsyarea(Figure5A),withRBCcomprising1.76 0.79%
(Figure 5B) and ﬁbrin 0.75 0.10% (Figure 5C). In contrast,
early biopsies of baboons transplanted with GTKO/
CD55-CD59-HT NICC demonstrated minimal clotting, red
cell sequestration and ﬁbrin deposition; the mean percent-
age of clot was signiﬁcantly lower (0.79 0.12%, p<0.05
vs. WT) (Figure 5A), with signiﬁcantly fewer RBC
(0.79 0.13%, p<0.05 vs. WT) (Figure 5B) and less ﬁbrin
(0.07 0.02%, p<0.05 vs. WT) (Figure 5C). By 8h
posttransplant, the mean percentage of clot in WT NICC
xenograft biopsies was 3.95 1.18% of the total biopsy
area (Figure 5D), with RBC 3.39 1.19% (Figure 5E) and
ﬁbrin 0.65 0.08% (Figure 5F). This was signiﬁcantly
greater than that observed in GTKO/CD55-CD59-HT NICC
xenograft biopsies (mean percentage of clot 0.5 0.10%,
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Figure 4: Degree of inﬁltration of GTKO/CD55-CD59-HT NICC
xenografts by T and B cells at 1h, 2 weeks and 1 month
posttransplant. GTKO/CD55-CD59-HT, GTKO pigs expressing
human CD55, CD59 and a1,2-fucosyltransferase (H-transferase,
HT); NICC, neonatal islet cell clusters.
Figure 5: Reduction in total clot formation (A and D), including both red blood cell sequestration (B and E) and ﬁbrin deposition (C and F), in
GTKO/CD55-CD59-HT NICC versus WT NICC xenografts. Quantitative computer image analysis was used to quantify the degree of
thrombosis around the grafts at 1–3h (A–C) and up to 8h (D–F) posttransplant. Data are shown as mean SEM of the total percentage
of the biopsy area.  p 0.05,   p 0.01,    p 0.001. GTKO/CD55-CD59-HT, GTKO pigs expressing human CD55, CD59 and
a1,2-fucosyltransferase (H-transferase, HT); NICC, neonatal islet cell clusters.
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WT, Figure 5E; ﬁbrin 0.2 0.02%, p<0.05 vs. WT,
Figure 5F).
Mechanism of clotting
Comparison of the fold change in the systemic platelet
count demonstrated greater early consumption in baboons
transplanted with WT NICC than in those transplanted
with GTKO/CD55-CD59-HT NICC (Figure 6A). There was a
signiﬁcantdecreasein platelet countin bloodsampledfrom
both the hepatic and portal veins within 20min following
transplantation of WT NICC. This consumption of platelets
continued to 6h posttransplant (Figure 6B).
Complement activation and thrombin generation were also
measured in vitro by incubating NICC with baboon PPP.
GTKO/CD55-CD59-HT NICC triggered signiﬁcantly less
complement activation than WT NICC (Figure 7A), and
generated signiﬁcantly less thrombin than WT NICC, as
demonstrated by reduced endogenous thrombin potential
(Figure 7B).
Development of xenoreactive antibodies
The antibody response to GTKO/CD55-CD59-HT NICC was
investigated by measuring serum IgM and IgG binding to
GTKO pig aortic endothelial cells by ﬂow cytometry.
Marked increases in anti-pig IgM and IgG were observed
at or after day 14 in three and two of the ﬁve recipients,
respectively (Figure 8). The reason for the inconsistent
antibody response is unclear, although it may be due to
inter-individual variability between recipients, for example,
in the absorption of immunosuppressive drugs.
Discussion
Thisistheﬁrststudyreportingthefateofneonatalpigislets
after intraportal transplantation into baboons. WT NICC
induced a profound and rapid thrombotic response, more
severe than IBMIR observed after human islet allotrans-
plantation (6). Despite the use of prophylactic anti-coagu-
lant therapy, human islet allotransplantation can cause
portalveinthrombosis(23,24).Pigisletxenograftsarelikely
to be more thrombogenic because of the multiple antigenic
differences and receptor-ligand incompatibilities between
pig and human coagulation pathways (25). Two previous
studies have examined adult pig islet intraportal xenografts
in baboons; in both cases, the islets were lost early to
rejection despite heavy immunosuppression, suggesting
that destruction was due to activation of the innate rather
than the acquired immune response and consistent with
our ﬁndings of a strong and widespread IBMIR (26,27). WT
NICC have been transplanted intraportally into maca-
ques (14,28,29), but IBMIR was not speciﬁcally examined
in those studies. Baboons, which are closer in size to
humans, may have subtle but important differences in their
coagulation response compared to macaques. Further-
more, most of the data describing coagulation abnormali-
ties following vascularized organ xenotransplantation have
been obtained in baboon recipients (17,30).
Liver biopsies taken within 60min of transplantation
showed WT NICC within the portal vasculature surrounded
by a dense ﬁbrin clot and heavily inﬁltrated by neutrophils.
This intimate interlinking of the inﬂammatory and coagula-
tion pathways is similar to other innate responses seen
in mammals, in particular the response to sepsis (31).
Excessivecoagulationactivatestheinﬂammatoryresponse
via G protein-coupled protease-activated receptors, which
can lead to up-regulation of tissue factor in monocytes and
neutrophils,providingamolecular link betweencoagulation
and inﬂammation (32,33). Monocytes and neutrophils have
high levels of inducible tissue factor, which can be up-
regulated rapidly to drive a positive feedback loop for
coagulation (32–34).
rhAT, previously shown to be effective at inhibiting
coagulopathy after renal xenotransplantation in ba-
boons (17), was ineffective at preventing the intraportal
clotting induced by WT NICC. This suggests that antibody
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Figure 6: Changes in systemic and portal platelet count early
after intraportal NICC xenotransplantation. Recipients of WT
NICC (n¼4) had signiﬁcantly lower systemic platelet counts than
recipients of GTKO/CD55-CD59-HT NICC (n¼5) (A). The reduction
in platelets was particularly pronounced in the hepatic blood
samples of the WT NICC recipients (B). Data are shown
as mean SD.  p 0.05,   p 0.01,    p 0.001. GTKO/CD55-
CD59-HT, GTKO pigs expressing human CD55, CD59 and a1,2-
fucosyltransferase (H-transferase, HT); NICC, neonatal islet cell
clusters.
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overcome the anti-thrombotic effects of anti-thrombin.
Surprisingly, analysis of 1-h liver biopsies revealed that
most NICC remained in the venules of the portal system.
The relatively low portal pressure (<5mmHg) may be
insufﬁcient to force the NICC into the sinusoids, and there
may be stasis upstream due to localized obstruction. This
is commonly seen in reduced wedged venous hepatic
pressures in our clinical islet transplant patients.
The effectiveness of genetic modiﬁcations that do not
directly target coagulation might not be expected to have a
major impact on IBMIR, given that thrombosis predom-
inates. However, there is signiﬁcant cross-talk between
complement activation—a very early component of IB-
MIR—and coagulation, and it has been shown previously
that inhibition of complement suppresses thrombin gener-
ation associated with intraportal islet transplantation in
rats (35). Furthermore, complement inhibition signiﬁcantly
inhibits the expression of active tissue factor by
neutrophils (36).
We recognize the potential limitations associated with the
experimental design. Although the increased resistance of
GM NICC to humoral immunity in vitro suggested that the
genetic modiﬁcations contributed to the protection against
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between the groups, in particular the use of immunosup-
pression and smaller recipients. On the latter point,
although the recipients of GM NICC received more NICC
per kilogram body weight, one might anticipate a greater
propensityforthrombosisinthesesmallerrecipientsdueto
a higher risk of stasis induced by mechanical obstruction.
Despite this, they showed markedly less thrombosis,
suggesting that stasis due to obstruction was not the
major contributor to clotting in this model.
Another caveat is that we used nondiabetic baboons and
therefore could not monitor the maturation and function of
the transplanted NICC. Our rationale was that we did not
require diabetic animals to obtain proof of inhibition of
IBMIR and short-term survival of the GM NICC. Further-
more, we were not expecting the grafts to mature
sufﬁciently to control blood glucose within the time frame
of the experiments, and the study was designed to assess
histological evidence of survival. Our results provide the
basis for future functional studies using diabetic recipients.
Finally, the data do not allow us to establish which of the
three genetic modiﬁcations provide an anti-IBMIR effect.
Cardiac xenotransplantation studies suggest that CD55
adds beneﬁt to the GTKO background (37), but there are no
corresponding data from islet xenotransplantation. Trans-
genicexpressionofhumanCD46improvedsurvivaloflong-
term adult pig islet xenografts in cynomolgus monkeys, but
had little impact on IBMIR (15). However, differences
between that study and the current study (e.g. recipients,
isletmaturity,presence/absenceofaGal)makeitdifﬁcultto
directly compare the two.
Even though the GTKO/CD55-CD59-HT NICC avoided
IBMIR, presumably allowing more NICC to survive the
initialtransplantperiod,theyweredestroyedwithin1month
by T cell–mediated cellular mechanisms despite the use of
an immunosuppressive protocol that we have demonstrat-
ed to be safe and effective in clinical human islet
allotransplantation (19). The long-term aim is to focus on
genetic modiﬁcation of the donor NICC to achieve better
survival rather than rely on unacceptably high and toxic
immunosuppressive protocols. Histology of the xenografts
2–4 weeks after transplantation showed progressive
inﬁltration by T and B cells. In addition, most recipients
had elevated anti-pig antibody titers, conﬁrming a T cell–
mediated B cell response. This suggests that GM pig NICC
provoked strong T cell–mediated rejection and additional
strategies will be required to promote long-term islet
xenograft survival. These might include less conventional
immunosuppressive regimens including costimulation
blockade, which has met with some success in the pig-
to-macaque and pig-to-cynomolgus monkey mod-
els (14,15,28,29). Another attractive possibility is further
genetic manipulation of the donor pig to suppress the
T cell–mediated response, for example by the transgenic,
graft-mediated local expression of immunosuppressive
agents such as CTLA4-Ig (38) or anti-CD2 mAb (39). This
inherent advantage needs to be utilized further if islet
xenotransplantation is to be brought successfully to the
clinic.
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Figure S1: Staining of isolated NICC for human CD55 (A)
and CD59 (B) ( 40 magniﬁcation).
Figure S2: One-hour liver biopsy of GTKO/CD55-CD59-
HTNICCrecipient,showingabsenceofthrombosisand
proximity of an NICC to the vessel wall.
FigureS3: Two-weekliverbiopsy ofGTKO/CD55-CD59-HT
NICC recipient, stained for chromogranin A (A), insulin (B),
glucagon (C), somatostatin (D), CD3 (E) and CD20 (F).
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